Abstract
Erlotinib could be a new option for the first-line treatment of non-small-cell lung cancer (NSCLC) according to data presented by C Zhou (Shanghai, China) and colleagues. In this phase 3 trial, 165 patients with epidermal growth factor receptor activating mutations were randomly assigned to treatment with either erlotinib alone or carboplatin plus gemcitabine. 154 of these patients were included in the presented analyses: 82 in the erlotinib group and 72 in the carboplatin and gemcitabine group. Progression-free survival [PFS] was significantly improved with erlotinib compared with the control group (median PFS 13·1 vs 4·6 months; hazard ratio [HR] 0·16, 95% CI 0·10–0·26; p<0·0001). There was a lower incidence of adverse events, and serious adverse events, with erlotinib than in the control arm; no patients had unexpected adverse events or showed signs of interstitial lung disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
